



---

## **Urogen N.A. and S. Grant Mulholland, M.D. to Collaborate on URG301 Drug Development Project for Overactive Bladder**

---

Burlingame, CA--June 13, 2007--Urogen N.A., Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders, announces that S. Grant Mulholland, M.D. has accepted the role of Lead Consultant for its URG301 drug development program targeting acute urgency associated with overactive bladder in women.

Over the past 30 years, Dr. Mulholland has achieved international recognition for his interest and expertise in urologic oncology and general urology. Dr. Mulholland is a member of numerous urologic, oncologic and surgical organizations, including the past President of the Philadelphia Urologic and Mid-Atlantic Section of the American Urological Association. Dr. Mulholland has also authored over 180 articles, chapters and books.

"Urogen is very pleased to have Dr. Mulholland join our drug development team for the URG301 project, with his recognized expertise in managing urologic disorders such as overactive bladder," said Dennis Giesing, PhD, Director of Product Development at Urogen N.A. "We look forward to a successful collaboration in the development of URG301 to provide the relief patients seek from the acute urgency and frequency they experience due to overactive bladder."

Overactive bladder is a medical condition caused by involuntary bladder muscle spasms and affects 20% of women over the age of 45. While not life-threatening for the individual, an overactive bladder is inconvenient, potentially embarrassing, and may disrupt sleep, while significantly impacting quality of life. Sufferers of overactive bladder are often afraid to leave their home or unable to participate in a lengthy meeting, dinner, or social event. Unfortunately, many of these people hesitate to seek treatment because they think their symptoms are a normal part of aging. This mindset is incorrect, as overactive bladder is not normal, is treatable, and treatment can significantly ease symptoms and improve quality of life.

"Many of my patients that I have treated stop taking their oral OAB drug due to side effects," said Dr. Mulholland. "These patients simply cannot tolerate the drug or do not find the minimal benefit they receive to outweigh the negative side effects. I look forward to working with Urogen on the URG301 project to help develop a better treatment for the many sufferers of OAB."

## **About Urogen**

Urogen is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urogen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urogen's URG101 project targets chronic pelvic pain of bladder origin which affects approximately 10.5 million men and women in North America. Urogen's URG301 project targets acute urgency in patients diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency. For further information, please visit Urogen's website at <http://www.urogen.com>.

## **Forward-Looking Statement**

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urogen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urogen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and securityholders are cautioned not to place undue reliance on such forward-looking statements. Urogen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

## **Contacts:**

Urogen N.A., Inc.  
Martin E. Shmagin  
Chief Financial Officer  
Phone: 650-259-0239  
[www.urogen.com](http://www.urogen.com)

The Investor Relations Group  
Investor Relations:  
Adam Holdsworth/Rachel Colgate  
Phone: 212-825-3210